2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses how community oncologists can incorporate the NCCN Guideline for Myeloproliferative Neoplasms (MPNs) into clinical practice.
Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses how community oncologists can incorporate the NCCN Guideline for Myeloproliferative Neoplasms (MPNs) into clinical practice.
Mesa hopes that the guidelines will be useful to physicians who are treating patients with MPNs. Moreover, he recognizes that trying to keep track of the various hematologic malignancies and their corresponding therapies are very challenging. The guidelines aim to help guide physicians during key decision points during treatment.
In patients for whom there is uncertainty as to which therapy they should receive, the guidelines can be a useful tool. For those who are on the fence with transplantation, discussing ideas with other physicians can be beneficial, Mesa adds.